GlassScriptPhysician profile
Deborah A Loney
NPI 1356658595
$7,402.94
in general payments reported to CMS, 2019-2025
14 companies · $1,231 in 2025
The $1,231 reported for 2025 was more than what 83% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,787 · 2020: $103 · 2021: $18.88 · 2022: $249 · 2023: $1,341 · 2024: $2,672 · 2025: $1,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,800 · Food and Beverage: $2,327 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,800.05 |
| Food and Beverage | $2,327.03 |
| Education | $117.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,986.68 | 2023-2025 | Inspire |
| Intersect Ent, INC. | $1,567.82 | 2019 | |
| Aerin Medical INC. | $1,533.87 | 2019-2024 | |
| Optinose US, INC. | $382.26 | 2019-2025 | |
| Medtronic, INC. | $271.84 | 2022-2024 | Propel, Sinuva |
| Regeneron Healthcare Solutions, INC. | $231.10 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $128.00 | 2022-2025 | Nucala |
| Stryker Corporation | $89.79 | 2019-2022 | |
| Smith+Nephew, INC. | $70.95 | 2019-2024 | Tula |
| Acclarent, INC | $58.04 | 2019-2020 | |
| Olympus America INC. | $23.55 | 2023 | |
| Genzyme Corporation | $22.40 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $19.88 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $16.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Loney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.